menu
    • menu
    [{"orgOrder":0,"company":"Theramex","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":6.9400000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":6.9400000000000004,"dosageForm":"Tablet","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"ObsEva","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linzagolix","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Flaxeed","moa":"||Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theramex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Theramex","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"11","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"ObsEva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"ObsEva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theramex \/ ObsEva","highestDevelopmentStatusID":"10","companyTruncated":"Theramex \/ ObsEva"},{"orgOrder":0,"company":"Theramex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theramex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Theramex"},{"orgOrder":0,"company":"Theramex","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2025","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Theramex \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Theramex \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Theramex","sponsor":"Endoceutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pessary","sponsorNew":"Theramex \/ Endoceutics","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Endoceutics"},{"orgOrder":0,"company":"Theramex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Nomegestrol Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theramex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Enzene Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Undisclosed","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Theramex \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Theramex \/ Theramex"}]

    Find Clinical Drug Pipeline Developments & Deals by Theramex

    Menu

    Theramex

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Daré Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Dar© Bioscience and Theramex Announce Co-Development for Contraceptive Implant

                            Details : Under the licensing agreement, Dare will develop Casea S (etonogestrel), a potential first-in-category contraceptive candidate for women.

                            Product Name : Casea S

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            February 20, 2025

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Daré Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Recipient : Radius Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Radius Expands Abaloparatide License with Theramex to New Territories

                            Details : Under the licensing agreement, Radius granted Theramex the exclusive commercialization rights to Eladynos (abaloparatide), indicated for the treatment of osteoporosis in postmenopausal

                            Product Name : Eladynos

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Abaloparatide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Recipient : Radius Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Medroxyprogesterone Acetate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : Ginefiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol wi...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : Medroxyprogesterone Acetate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : Ginefiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dydrogesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® from Viatris, Inc.

                            Details : Through the agreement, Viatris divests its rights to women's healthcare products Duphaston (dydrogesterone) and Femoston (estradiol/dydrogesterone) to Theramex.

                            Product Name : Duphaston

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            October 10, 2023

                            Lead Product(s) : Dydrogesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Recipient : Radius Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼i...

                            Details : Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , A...

                            Product Name : Tymlos

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            March 20, 2023

                            Lead Product(s) : Abaloparatide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Recipient : Radius Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dydrogesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Viatris

                            Deal Size : $6,940.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total ...

                            Details : Through the agreement, Viatris divests its rights to women's healthcare products Duphaston (dydrogesterone) and Femoston (sstradiol/dydrogesterone) to Theramex and its Women's Healthcare business, primarily related to oral and injectable contraceptives, ...

                            Product Name : Duphaston

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            January 10, 2023

                            Lead Product(s) : Dydrogesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Viatris

                            Deal Size : $6,940.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : ObsEva

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Theramex Announces Licensing Agreement with ObsEva for the Commercialisation of Linzagolix for the Treatment o...

                            Details : Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids. Linzagolix is also in development as a potential treatment for endometriosis-associated pain. Linzagolix is not currently approved for any indication anywhere in the world.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 02, 2022

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : ObsEva

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tofu Extract,Flaxeed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Theramex Launches Non-hormonal Femarelle® on the 12th of May

                            Details : Femarelle® is a non-hormonal food supplement developed to help women manage symptoms in perimenopause, products cover all menopause stages to improve symptoms and women's bone health and will be available in different countries.

                            Product Name : Femarelle

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 05, 2022

                            Lead Product(s) : Tofu Extract,Flaxeed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : ObsEva

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonis...

                            Details : Yselty (Linzagolix) is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.

                            Product Name : Yselty

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 17, 2022

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : ObsEva

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Recipient : ObsEva

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatm...

                            Details : ObsEva has entered into a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in Europe. Theramex’s extensive women’s health commercial infrastructure includes a dedicated sales force of more than ...

                            Product Name : Yselty

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 25, 2022

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Recipient : ObsEva

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth